Acino strengthens its operations in Saudi Arabia after sustained growth in the Middle East and Africa
RIYADH — Acino, a leading provider of high-quality pharmaceutical products and services, today announced its expansion into the Kingdom of Saudi Arabia by establishing a legal entity and office in Jeddah.
This decision is part of the company’s growth strategy in the Middle East, Turkey and Africa in pursuit of its mission to provide access to high quality medicines for the benefit of patients.
The announcement was made during an event that took place at the office of the Ministry of Investment of Saudi Arabia (MISA). Among the delegates present were Dr. Sara Althari, Managing Director and Advisor at MISA; His Excellency Abdullah Al Masoud, Saudi Commercial Attaché in Switzerland; Steffen Saltofte, CEO, Acino; Dr. Andrew Bird, Managing Director and Regional Head, Middle East, Turkey and Africa, Acino; and Fahad Al Otaibi, Country Manager for Saudi Arabia, Acino.
“Biotechnology and healthcare are at the forefront of our national priorities, and we are committed to partnering with global pharmaceutical companies to bring the highest quality healthcare and industry expertise to the Kingdom,” said Dr. Sara Althari, Director General of Biotechnology and Pharma, Saudi Arabia’s Ministry of Investment. “We welcome the expansion of Acino’s operations and footprint in the Kingdom and are deeply encouraged by the company’s commitment to investing in our healthcare ecosystem. Acino has a strong track record of delivering advanced drug delivery technologies to the region, and we believe this is the beginning of a lasting and meaningful partnership between Acino and the Kingdom of Saudi Arabia.
In 2017, Acino marked its presence in the Kingdom by creating a scientific office. The decision to expand further into the country follows strong demand for its products and services. The company’s plans in Saudi Arabia include bringing global expertise to the Kingdom as well as hiring nationals as part of its investments in human resources and scientific activities.
Acino will also explore opportunities to collaborate with local manufacturers and produce certain drugs in the country. The Jeddah office will fulfill its mission to provide access to affordable, high-quality medicines for national and expatriate patients, as well as support the country’s upcoming health sector transformation agenda under the National Vision 2030.
“Acino is committed to the world to advance the development of healthcare by accelerating time to market and patient access to high-quality medicines that all stakeholders can trust,” said said Steffen Saltofte, CEO of Acino. “We work closely with Ministries of Health, manufacturers and a wide range of healthcare professionals to improve the quality of care and improve treatment outcomes. Our arrival in Saudi Arabia has received the warm support of the Ministry of Investment and builds on the renewed momentum of the Government of Saudi Arabia in its plans to improve the health sector.
© Copyright 2022 The Saudi Gazette. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).